CSS
BPMC

Cubist Systematic Strategies’s Blueprint Medicines BPMC Stock Holding History

Cubist Systematic Strategies’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,700
Closed -$620K – 3002
2024
Q3 		$620K Sell
6,700
-2,400
-26% -$238K ﹤0.01% 2110
2024
Q2 		$981K Sell
9,100
-200
-2% -$20K 0.01% 1749
2024
Q1 		$882K Buy
9,300
+3,400
+58% +$292K 0.01% 2262
2023
Q4 		$544K Buy
+5,900
New +$382K ﹤0.01% 2479

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cubist Systematic Strategies's BPMC Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 46,602 shares — an estimated $5.97M sold.

Cubist Systematic Strategies first reported a position in BPMC in Q1 2017 and held it in 22 quarters. The position peaked at $5.97M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 46,602 Blueprint Medicines shares in Q3 2025, an estimated $5.97M.
  • Cubist Systematic Strategies first reported a position in Blueprint Medicines in Q1 2017 and held it in 22 quarters.
  • Cubist Systematic Strategies's Blueprint Medicines position peaked at $5.97M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.